The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
hou e xing zhong liu de ba xiang zhi liao jin zhan
Author(s): 
Pages: 2168-2171
Year: Issue:  13
Journal: The Journal of Practical Medicine

Abstract: 喉癌是头颈部常见的恶性肿瘤,约占头颈部肿瘤的13.9%。喉癌外科治疗已有100多年历史,但对于中、晚期和复发患者,常规治疗的疗效却不尽人意,其局部复发率、远处转移率及5年存活率分别是27%~61%、18%~31%、27%~34%[1]。此时,放化疗就显得尤为重要,但是目前的大多数抗肿瘤药物靶向性不够明显,治疗过程中对正常组织造成不可逆的损害,降低人体的免疫能力,从而降低了疗效。因此,增加肿瘤组织对药物敏感性、提高抗肿瘤药物疗效和减少药物毒副作用的靶向治疗成为目前恶性肿瘤治疗的研究热点。
Related Articles
No related articles found